# DESCRIPTION

## FIELD OF THE INVENTION

- define field of small molecular entities

## BACKGROUND

- introduce T cell receptor and MHC molecules
- describe CD1 molecules and lipid/glycolipid antigens
- introduce MR1 and its conservation
- describe CD1 presenting small molecules from microbes
- introduce MR1-restricted T cells and MAIT cells
- discuss limitations of MAIT cells

## SUMMARY OF THE INVENTION

- introduce MR1-restricted T cells and their function
- summarize invention of identifying MR1 ligands using mass spectrometry

## DETAILED DESCRIPTION OF THE INVENTION

- define compounds of Formula 1a, Formula 2a, Formula 1b, and Formula 2b
- specify R1, R2, and R3 for compounds of Formula 1a, Formula 1b, Formula 2a, and Formula
- provide additional compounds of Formula 1a, Formula 1b, Formula 2a, and Formula 2b
- specify R1, R2, and R3 for additional compounds of Formula 1a, Formula 1b, Formula 2a, and
- provide further compounds of Formula 1a, Formula 1b, Formula 2a, and Formula 2b
- specify R1, R2, and R3 for further compounds of Formula 1a, Formula 1b, Formula 2a, and
- provide additional compounds of Formula 1a, Formula 1b, Formula 2a, and Formula 2b
- specify R1, R2, and R3 for additional compounds of Formula 1a, Formula 1b, Formula 2a, and
- provide further compounds of Formula 1a, Formula 1b, Formula 2a, and Formula 2b
- specify R1, R2, and R3 for further compounds of Formula 1a, Formula 1b, Formula 2a, and
- provide compounds of Formula 3a and Formula 3b
- specify R4, R5, R6, and R7 for compounds of Formula 3a and Formula 3b
- provide additional compounds of Formula 3a and Formula 3b
- specify R4, R5, R6, and R7 for additional compounds of Formula 3a and Formula 3b
- provide further compounds of Formula 3a and Formula 3b
- specify R4, R5, R6, and R7 for further compounds of Formula 3a and Formula 3b
- provide additional compounds of Formula 3a and Formula 3b
- specify R4, R5, R6, and R7 for additional compounds of Formula 3a and Formula 3b
- provide further compounds of Formula 3a and Formula 3b
- specify R4, R5, R6, and R7 for further compounds of Formula 3a and Formula 3b
- provide specific compounds of Formula 3a and Formula 3b
- describe tautomers of compounds
- specify R6 for compounds of Formula 3a and Formula 3b
- specify R6 and R7 for compounds of Formula 3a and Formula 3b
- describe 5-10-membered carbocycle and heterocycle
- provide method of treating respiratory bacterial pathogen infections
- provide method of treating Mycobacterium tuberculosis infections
- provide method of treating Streptococcus pyogenes infections
- provide method of treating enteric biological infections
- provide method of treating E. coli infections
- provide method of treating Salmonella infections
- provide pharmaceutical compositions
- provide individual methods for preparing medicaments
- provide use of compounds as vaccines

### Terms

- define FO
- describe FO synthesis
- describe FO binding to MR1
- introduce DZ
- describe DZ binding to MR1
- introduce photolumazines
- describe photolumazine binding to MR1
- define binding
- describe detection of binding
- define cancer
- describe characteristics of cancer
- define metastatic disease
- describe pathology of cancer
- define effective amount
- describe response to effective amount
- define subject
- describe treatment of disease
- define ameliorating
- describe prophylactic treatment
- describe therapeutic treatment
- define tumor
- introduce pharmaceutical compositions
- describe formulation of pharmaceutical compositions
- describe additives for pharmaceutical compositions
- describe tonicity adjustment
- describe carrier selection
- describe release of compound
- describe time release formulations
- describe controlled release binders

### Treatment

- disclose treatment methods
- describe administration routes
- specify administration forms
- outline prophylactic and therapeutic purposes
- describe dosage regimens
- define effective amount
- specify factors affecting effective amount
- provide non-limiting dosage ranges
- outline determination of effective amount
- describe animal model studies
- guide administration protocols

## EXAMPLES

- provide illustrative examples

### Example 1—the Microbial MR1 Ligandome

- generate chimeric MR1 protein
- express and analyze hpMR1 protein
- infect insect cells with E. coli or M. smegmatis
- analyze ligand repertoire of hpMR1
- generate tetrameric hpMR1
- stain MR1Ts with hpMR1 tetramers
- identify MR1Ts in human peripheral blood mononuclear cells
- compare hpMR1+EC tetramer+ cells with TRAV1-2+ cells
- stimulate MR1T cell clones with hpMR1 tetramers
- examine reactivity of MR1Ts in whole PBMC
- correlate frequency of tetramer+ cells with IFN-γ response
- assess presence and abundance of known MR1T ligands
- identify MR1T ligands by tandem mass spectrometry
- analyze relative abundance of MR1T ligands
- evaluate all ligands eluted from hpMR1 using LCMS
- identify putative microbial-derived ligands
- assist in identification of novel ligands using GNPS
- identify novel MR1 ligands
- introduce microbial MR1 ligandome
- test riboflavin and FO for MR1T cell activation
- determine antagonistic properties of riboflavin and FO
- test PLI and PLIII for MR1T cell activation
- associate discrete TCR usage with ligand discrimination
- test expanded panel of TCR diverse MR1T clones
- demonstrate discrete MR1T TCRs distinguish between distinct MR1 antigens
- discuss MR1 sampling of microbial metabolome
- discuss selective TCR usage associated with microbes
- note MR1/5-OP-RU tetramer limitations
- discuss implications for immunotherapeutic or vaccination strategies
- disclose work on MR1 ligand diversity
- detect MR1 ligand diversity using MR1T cells
- perform mass spectrometric analysis of microbially-derived MR1 ligands
- identify shared and unique ligands using GNPS analysis
- test riboflavin, FO, PLI, and PLIII as novel MR1 ligands
- discuss selective recognition of ligands by MR1Ts with distinct TCRs
- discuss diversity in MR1T TCRs for broad MR1 ligand recognition
- note MR1/5-OP-RU tetramer limitations
- discuss avenues for further exploration of MR1T function and ligand recognition
- discuss selective TCR usage associated with microbes
- discuss molecular basis for selective ligand recognition
- present example of microbial MR1 ligandome
- show MR1T cell responses to synthetic ligands
- express and validate hpMR1
- analyze hpMR1 tetramer staining of MR1T cell clone
- present raw LCMS data for 5-OP-RU/rRL-6CH2OH
- present raw LCMS data for RL-6-Me-7-OH
- present raw LCMS data for 5-OE-RU
- present raw LCMS data for RL-6,7-diMe
- show intensities of previously identified ligands
- present complete GNPS molecular network
- present raw LCMS data for Ac-RL-6-Me-7-OH
- present raw LCMS data for 6-hydroxy-riboflavin
- present raw LCMS data for 8-demethyl-8-hydroxy-riboflavin
- present raw LCMS data for 8-demethyl-8-formyl riboflavin
- present raw LCMS data for riboflavin
- present raw LCMS data for 7,8-didemethyl-8-hydroxy-5-deazariboflavin (FO)
- present raw LCMS data for 6-(1H-indol-3-yl)-7-hydroxy-8-ribityllumazine (
- present raw LCMS data for 6-(2-carboxyethyl)-7-hydroxy-8-ribityllumazine (PLI)
- describe chemical synthesis of MR1 ligands
- show ion structures of identified or proposed compounds
- conclude example of microbial MR1 ligandome

